Search

Charles Hsu CHARLES HSU, Johns Hopkins University, Baltimore Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a

Zulfiqar Bhutta Reference: The Lancet, Maternal and Child Undernutrition Special Series With one child in three killed by it, childhood and maternal undernutrition are discussed in a special series of

Colin Baigent REFERENCE: Lancet 371:117 January 11, 2008 COLIN BAIGENT, Oxford University Statins were found to cut cardiovascular event rates by a fifth among patients with both Type I and Type II di

Peter Tyrer REFERENCE: Lancet 371:57 January 5, 2008 PETER TYRER, Imperial College, W6 8RP London A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients

Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu

Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in

Stephen Jones STEPHEN JONES, US Oncology Research, Houston Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival adva

Anton Hagenbeek ANTON HAGENBEEK, University Medical Centre Utrecht For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free surv

Christian Geisler CHRISTIAN GEISLER, Rigshospitalet, Copenhagen Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek T

Susan O’Brien SUSAN O’BRIEN, MD Anderson Cancer Center, Houston For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamid

Richard Stone RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute New data shows that dasatinib is giving durable responses in patients with chronic phase

Pierre Fenaux PIERRE FENAUX, Paris 13 University Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with